Johnson & Johnson (JNJ) likely to feel the pinch in Q3
Johnson & Johnson (NYSE: JNJ) is slated to release its third-quarter earnings results on Tuesday, October 15, before the market...
Health Care
What to expect when UnitedHealth reports Q3 earnings
UnitedHealth Group (NYSE: UNH) is scheduled to report third quarter 2019 earnings on Tuesday, October 15, before the market opens....
SmileDirectClub stock hits its lowest since IPO amid analyst initiations
SmileDirectClub (NASDAQ: SDC) stock has fallen 32% to $11.20 on Tuesday, which is the teledentistry company’s lowest since the initial...
Pfenex shares shoot up on getting FDA approval for its osteoporosis drug
Shares of Pfenex (NYSE: PFNX) jumped over 15% in today’s pre-market trading session as the clinical-stage biotech company received approval...
Two zero-revenue biotech stocks debut in a shaky IPO market
The IPO market has recently been pretty unwelcoming, with some of the popular firms going dud right after their debut....
Strong pipeline and innovation make Novartis a sure bet, despite setbacks
The uncertainties surrounding drug development and intense competition are the primary challenges facing pharmaceutical companies, which also prompt investors to...
Rite Aid swings to profit in Q2, stock gains strength
Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in...
Ovid Therapeutics stock gains on positive epilepsy trial data
Ovid Therapeutics Inc. (NASDAQ: OVID) stock climbed to an 8-month high of $3.05 on Tuesday after positive initial data from...
Wall St expecting a turn-around quarter from Rite Aid in Q2
Things haven’t been working out so well for Rite Aid (NYSE: RAD) since the past three years. The company’s inability...
Will Zynerba Zygel trial be extended amid safety warning?
Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol...
Three companies that are haunted by multiple lawsuits
Several companies have battled lawsuits from time to time for various reasons. However, sometimes companies face thousands of lawsuits for...
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be...
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which...
Will Allergan-AbbVie merger be intercepted
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing...
SmileDirectClub goes public; opens 11% below its IPO price of $23
Dentistry company SmileDirectClub (NASDAQ: SDC) opened at $20.55, down 11% from its IPO price of $23 on its debut day....
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date...
Earnings preview: Market has low expectations ahead of Advaxis’ Q3 report
Advaxis (NASDAQ: ADXS), a late-stage biotech firm, is one of the worst-performing healthcare stocks that continuously disappointed investors over the...
Novartis scores another point in multiple sclerosis therapy, stock rises
Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of...
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as...
4 biotech stocks that are ideal takeover targets
Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years...
Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates
Generic drug manufacturer Lannett’s (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company’s bottom...